Public policy statement on Office-Based Opioid Agonist Treatment (OBOT).
D000553:Ambulatory Care / Q000331:legislation & jurisprudence*; D002047:Buprenorphine / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003191:Comprehensive Health Care / Q000331:legislation & jurisprudence*; D003266:Continuity of Patient Care / Q000331:legislation & jurisprudence; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004502:Education, Medical, Continuing / Q000331:legislation & jurisprudence; D006556:Heroin Dependence / Q000534:rehabilitation; D006801:Humans; D008691:Methadone / Q000627:therapeutic use*; D009294:Narcotics / Q000819:agonists* / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D010348:Patient Care Team / Q000331:legislation & jurisprudence*; D011320:Primary Health Care / Q000331:legislation & jurisprudence; D011613:Psychotherapy / Q000331:legislation & jurisprudence; D011640:Public Policy; D015813:Substance Abuse Detection / Q000331:legislation & jurisprudence; D016320:Substance Abuse Treatment Centers / Q000331:legislation & jurisprudence*; D014481:United States
D009294:Narcotics; D002047:Buprenorphine; D008691:Methadone